UCB: Oddo BHF raises target price
(CercleFinance.com) - Oddo BHF confirms its 'outperform' rating on UCB shares, with a target price raised by 10%, from E180 to E198, following the announcement that the Belgian laboratory has sold part of its mature product portfolio in neurology and allergy treatments in China.
In this, and in Bimzelx's distribution partnership in the same region, the analyst sees UCB's desire to allocate its capital specifically to its latest launches, and in particular to focus on Western markets so as not to spread itself too thin.
The key point of this announcement is the group's reconfirmation of a low- to-mid thirties 2025 EBITDA margin as a percentage of revenues, Oddo BHF adds, which also points to UCB's growth profile with a 2024-28 EPS CAGR of 33%.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.
The information and analyses published by Cercle Finance are intended solely as a decision-making aid for investors. Cercle Finance cannot be held responsible, directly or indirectly, for the use of information and analyses by readers. Uninformed investors are advised to consult a professional advisor before investing. This information does not constitute an invitation to sell or a solicitation to buy.
In this, and in Bimzelx's distribution partnership in the same region, the analyst sees UCB's desire to allocate its capital specifically to its latest launches, and in particular to focus on Western markets so as not to spread itself too thin.
The key point of this announcement is the group's reconfirmation of a low- to-mid thirties 2025 EBITDA margin as a percentage of revenues, Oddo BHF adds, which also points to UCB's growth profile with a 2024-28 EPS CAGR of 33%.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.
The information and analyses published by Cercle Finance are intended solely as a decision-making aid for investors. Cercle Finance cannot be held responsible, directly or indirectly, for the use of information and analyses by readers. Uninformed investors are advised to consult a professional advisor before investing. This information does not constitute an invitation to sell or a solicitation to buy.